Literature DB >> 18304612

Refractory central nervous system vasculitis and gastrocnemius myalgia syndrome in Crohn's disease successfully treated with anti-tumor necrosis factor-alpha antibody.

Sebastian Ullrich1, Susanne Schinke, Markus Both, Karl Christian Knop, Nancy Coula Kirkiles-Smith, Wolfgang Ludwig Gross, Peter Lamprecht.   

Abstract

BACKGROUND: Secondary vasculitis represents a rare extraintestinal manifestation of Crohn's disease (CD). Appropriate and prompt diagnosis is often delayed by uncertainties about the relationship of the vasculitic manifestations and CD.
OBJECTIVE: To describe our experience with vasculitis in CD and review the literature with respect to different manifestations and pathophysiological aspects of extraintestinal vasculitic manifestations of CD.
METHODS: We report 2 new cases of CD with secondary small-vessel vasculitis. We also extensively review the literature (1960-2007) using a broad range of key words related to secondary vasculitis in CD. Relevant publications were evaluated for the number of reported patients and manifestations of vasculitis.
RESULTS: Vasculitis is a rare extraintestinal manifestation of CD. Different types of vasculitis affect large-, medium-, and small-sized vessels associated with CD. Common immunologic features include intestinal inflammation as well as an infiltration of gammadelta-T-cells and/or Th1-type cells into vessel walls. The 2 new cases of secondary vasculitis in CD reported here reflect 2 major types of CD-related inflammatory vascular disorders. The first involves the central nervous system, while the second represents circumscribed Musculus gastrocnemius involvement (so-called "gastrocnemius myalgia syndrome"). Successful treatment of refractory secondary vasculitis in CD with an anti-tumor necrosis factor-alpha antibody is shown for the first time.
CONCLUSION: Vasculitis secondary to CD is an uncommon finding. Therefore, it has to be carefully differentiated from other forms of primary or secondary vasculitis with intestinal involvement. Treatment with an anti- tumor necrosis factor-alpha antibody may prove a treatment option in vasculitis as an extraintestinal manifestation of CD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18304612     DOI: 10.1016/j.semarthrit.2008.01.008

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  7 in total

1.  [Differential diagnosis of a vasculitic syndrome of the lower limb].

Authors:  Nikolas Ruffer; Martin Krusche; Marie-Therese Holzer; Christian Hagel; Ina Kötter
Journal:  Z Rheumatol       Date:  2021-07-09       Impact factor: 1.372

2.  Coronary artery ectasia in Crohn's disease.

Authors:  Theofanis Korovesis; George Katritsis; Panagiotis Koudounis; Theodoros Zografos
Journal:  BMJ Case Rep       Date:  2018-10-21

3.  Histologically confirmed case of cerebral vasculitis associated with Crohn's disease--a case report.

Authors:  Masayuki Gekka; Taku Sugiyama; Masafumi Nomura; Yasutaka Kato; Hiroshi Nishihara; Katsuyuki Asaoka
Journal:  BMC Neurol       Date:  2015-09-21       Impact factor: 2.474

4.  Crohns disease with central nervous system vasculitis causing subarachnoid hemorrhage due to aneurysm and cerebral ischemic stroke.

Authors:  Shaileshkumar S Garge; Pooja D Vyas; Pranav D Modi; Sharad Ghatge
Journal:  Ann Indian Acad Neurol       Date:  2014-10       Impact factor: 1.383

5.  Gastrocnemius Myalgia as a Rare Initial Manifestation of Crohn's Disease.

Authors:  Atsumu Osada; Hiroaki Yamada; Sayuri Takehara; Yuuichiro Tozuka; Taito Fukushima; Hiroyuki Oka; Hiroshi Okazaki; Shohei Nagaoka
Journal:  Intern Med       Date:  2018-02-28       Impact factor: 1.271

6.  Crohn's disease-related 'gastrocnemius myalgia syndrome' successfully treated with infliximab: A case report.

Authors:  Julien Catherine; Hazim Kadhim; Frédéric Lambot; Claire Liefferinckx; Virginie Meurant; Lukas Otero Sanchez
Journal:  World J Gastroenterol       Date:  2022-02-21       Impact factor: 5.742

7.  Cerebral granulomatosis as a manifestation of Crohn's disease.

Authors:  Konrad Whittaker; Konstanze Guggenberger; Nils Venhoff; Soroush Doostkam; Hans-Eckart Schaefer; Brita Fritsch
Journal:  BMC Neurol       Date:  2018-10-03       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.